From Jeff Wolf, MD & Tom Martin, MD: Grand MMTI

Grand MMTI - Speeding Development of Improved Multiple Myeloma Therapies
Remember to share!

From Jeff Wolf, MD & Tom Martin, MD: Grand MMTI

Because of generous donors like you, the UCSF Stephen & Nancy Grand Multiple Myeloma Translational Initiative (Grand MMTI) is pioneering groundbreaking treatments and leading world-changing medical research to help multiple myeloma patients lead long and healthy lives.

 

Who We Are

The Stephen and Nancy Grand Multiple Myeloma Translational Initiative (Grand MMTI), launched in 2009 and led by Jeff Wolf, MD and Tom Martin MD, is the premier myeloma translational program on the West Coast, with the goal of speeding development of improved multiple myeloma treatments. 

Grand MMTI physician-scientists are learning how to manipulate and harness a patient’s immune system to seek out and destroy cancer cells. The Grand MMTI is one of the few programs nationwide with the clinical trials expertise and capabilities to administer novel and promising multiple myeloma cellular immunotherapies to our patients.  Please click here to watch Grand MMTI leader Tom Martin, MD discuss CAR T-cell therapy, one type of immunotherapy offering new hope to relapsed/refractory patients.  Arun Wiita, MD, PhD is one of the scientists collaborating with the Grand MMTI is working hard to improve upon what has already been accomplished with these therapies. 

Join us, donate today and help us reach our goal of raising $50,000 by December 31. Your gift – and every gift to the Grand MMTI – makes a difference. It has the power to become the tipping point, when research discoveries are transformed into lifesaving care. On behalf of every patient and family member who battles this disease, thank you. Together, we are bringing new hope to cancer patients here and around the world.

Please contact Sydney Pietrzak, assistant director of development, to make your gift over the phone or with questions at Sydney.Pietrzak@ucsf.edu or (415) 502-1197. 

 

Six Program Pillars

  1. Basic Science Research - world renowned labs working on key projects addressing different aspects of multiple myeloma biology, treatment and patient stratification
  2. Clinical Research (trials) - specialists in first-in-human clinical trials with the expertise and facilities to support complex trials including cell-based therapies
  3. Translational Laboratory - evaluating novel therapies using cutting-edge technologies and multiple myeloma models
  4. Tissue Bank and Annotated Database - our extensive tissue bank contains samples representing all stages of disease progression allowing for in-depth analysis comparing experimental data to patient responses
  5. Industry Collaborations - working with industry is key in getting novel therapies to patients. We provide our industry partners with relevant models, data, scientific expertise and access to clinical key opinion leaders to drive therapeutic development
  6. Scientific Advisory Board - The Grand MMTI's Scientific Advisory Board (SAB) consists of internationally recognized myeloma clinicians and researchers, who provide scientific and strategic guidance on the Grand MMTI clinical and research programs.

 

Please learn more about our program by viewing the faculty presentations from our recent event on September 26, 2017:

Jeff Wolf, MD and Tom Martin, MD:  Welcome Introduction, and Program Overview – Our Path to the Present

Nina Shah, MD:  Myeloma Immunotherapy – From Chaos to Control

Sandy Wong, MD:  New Therapies for Amyloidosis – Shedding Light on Light Chains

Jason Gestwicki, PhD:  Laboratory Exploration of Novel Targets for Myeloma

Arun Wiita, MD, PhD:  Translational Lab – Taking Treatments from Bench to Bedside

Tom Martin, MD:  Developing CAR T-Cell Therapy – Our Road to the Future